News tagged with bortezomib

Related topics: multiple myeloma

Medication duloxetine helps reduce pain from chemotherapy

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April ...

Apr 02, 2013
popularity 4 / 5 (1) | comments 0

Possible new therapy for the treatment of myeloma

(Medical Xpress)—Research from Karolinska Institutet shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common ...

Sep 05, 2012
popularity not rated yet | comments 0 | with audio podcast

Bortezomib ups response, survival in multiple myeloma

(HealthDay) -- For patients with newly diagnosed multiple myeloma (MM), induction treatment with a combination of bortezomib, doxorubicin, and dexamethasone (PAD) followed by bortezomib maintenance therapy ...

Jul 23, 2012
popularity not rated yet | comments 0

Kyprolis approved for multiple myeloma

(HealthDay) -- Kyprolis (carfilzomib) has been approved by the U.S. Food and Drug Administration to treat certain people with multiple myeloma who have already been given at least two prior therapies.

Jul 20, 2012
popularity not rated yet | comments 0
  • Pages: 1

Bortezomib

Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.

This text uses material from Wikipedia licensed under CC BY-SA